Supratentorial primitive neuroectodermal tumors (sPNET) and atypical teratoid/rhabdoid tumors (AT/RT) of the CNS represent a biological and clinical enigma, despite advances in both molecular techniques and clinical management for these two rare embryonal brain tumors of childhood. Epigenetic changes hold great potential as possible disease mechanisms and may be manipulated therapeutically. We thus studied aberrant methylation of the genes RASSF1A and CASP8 and its consequence on expression in cell lines and primary tumors using a combination of semiquantitative methylation specific PCR (MSP), bisulfite sequencing and RT-PCR. In all, 17 samples of autopsy-derived normal appearing brain served as controls. Opposed to control tissues 19/24 sPNET and 4/6 AT/RT demonstrated aberrant methylation for the RASSF1A promoter region. Treatment of cell lines using 5-Aza-2 0 -deoxycytidine (5AZA) alone or in combination with trichostatin A (TSA) succeeded in re-establishing expression of RASSF1A in cell lines derived from a renal rhabdoid, an AT/RT and a medulloblastoma. A 5 0 CpG-rich region of CASP8 was methylated in normal tissues and in tumors. However, CASP8 showed inconsistent expression patterns in normal and tumor tissues. Our results indicate that aberrant methylation of the RASSF1A promoter region may be of importance in the origin and progression of sPNET and AT/ RT while the analysed 5 0 -CpG rich region of the CASP8 gene does not seem to play an important role in these tumors. Further studies of epigenetic changes in these rare tumors are warranted as their biology remains obscure and treatment efforts have been rather unsuccessfull.
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In contrast to adults who are mainly affected by epithelial cancers such as lung and breast carcinomas, children mostly suffer from embryonal malignancies. Among these the current WHO classification recognizes the following entities: medulloblastoma (MB) and its histological variants, supratentorial primitive neuroectodermal tumors (sPNET), ependymoblastomas, medulloepitheliomas and atypical teratoid/rhabdoid tumors (AT/RT) (Kleihues et al., 2002) . While MB account for 20-25% of all malignant brain tumors during childhood, sPNET and AT/RT represent rarities.
Consequently extensive molecular studies of sPNET are completely missing from the literature. The limited available data is derived from cytogenetic studies, that is, comparative genomic hybridization (CGH) demonstrating gains on chromosomes 4q (50%), 7 (30%) and 19q (30%); losses were detected in 4q (50%), 9 (40%), 13q (30%), 14q (30%), 18q (30%) and 19q (40%) (Russo et al., 1999) . Specific gene mutations in sPNET have not been described and studies in general suffer from rather limited sample numbers.
AT/RT, like rhabdoid tumors in other anatomical locations such as the kidney, are characterized by mutations of the gene SMARCB1 (hSNF5/INI1) localized to chromosome 22q11.2 . Small series using CGH demonstrated loss of chromosome 19q and in limited numbers of 16p, 17p and 20q. Specific genes at the respective loci have not yet been evaluated (Rickert and Paulus, 2004) .
We have previously demonstrated that sPNET share certain methylation target genes with MB, but may also show methylation in loci not affected in MB (Fru¨hwald et al., 2001a, b) . The only information on aberrant methylation in AT/RT is its absence in the promoter region of SMARCB1 .
RASSF1A and CASP8 have been described as very commonly epigenetically silenced by promoter methylation in the most common embryonal brain tumor of childhood, MB (Lusher et al., 2002; Zuzak et al., 2002) . In previous biological, clinical and epidemiological studies sPNET and AT/RT have mostly been coanalysed with MB. While AT/RT and sPNET share histopathological features with MB they clearly differ on a molecular level (Biegel et al., 1992; Russo et al., 1999; Fru¨hwald et al., 2001a) . In this study, we collected tissue samples of two large German centers (Muenster and Wuerzburg) derived from 24 sPNET and six AT/RT and evaluated aberrant methylation of RASSF1A and CASP8 and the potential consequences on gene expression. To strengthen our data, we employed an array of control tissues derived from different regions of the brain and from individuals of different age groups (Table 1) . We used human cerebellar tissue from newborn to 67 years and normal appearing cortical tissue from a newborn of 36 weeks gestational age to a 16-year-old. Since MSP using normal appearing brain tissues demonstrated methylation signals for CASP8 and at a much lower level also for RASSF1A, we employed a semiquantitative MSP analysis. As artificial in vitro methylation using SssI does not yield 100% methylated DNA (even though the error is in the range of 5%) we used a calibration series produced by mixtures of clones of MSP products that represent completely methylated and unmethylated DNA confirmed by sequencing at the ratios shown in Figure 1 . The resulting calibration series served as a template for comparison with the PCR bands of interest (Figure 1 ). The 1:1 reaction of methylated to unmethylated clones did not yield bands of equal intensity, as PCR reactions inescapably exhibit more or less different efficiencies.
Densitometric analysis of bands resulting from RASSF1A MSP revealed methylation between 1 and 2% in three cerebella and one cerebrum, below 0.06% in nine cerebella and three cerebra (Table 1, Figure 2) . One normal cerebral sample in a 5-year-old showed a deviating level of methylation reaching 33% (sample No 17 in Table 1 , Figure 2 ). In stark contrast tumor tissues exhibited methylation levels below 5% in only 4/24 sPNET and in 1/6 AT/RT (see Tables 2a and b) . Furthermore, we demonstrated aberrant methylation reaching 80-100% in 13/24 sPNET (54.2%) and in four of six AT/RT (66.6%). As the remaining 6/24 sPNET were methylated to 35-70% 20/24 sPNET (83.3%) displayed levels of methylation far above those observed for normal brain samples (Table 2b) .
To confirm the results of MSP and to assess the extent of aberrant methylation we performed bisulfite sequencing on samples for which enough good-quality DNA was available. Bisulfite sequencing of five clones each of three normal brain samples and five tumors (two sPNET and three AT/RT) revealed an excellent correlation with the MSP results ( Figure 3 ). All sPNET were methylated ALCL, anaplastic large cell lymphoma; AN, aortic aneurysm; AP, aspiration pneumonia; CHD congenital heart disease; CHF, congestive heart failure; dx, cause of death; GW, gestational weeks; MD, metabolic disease; nb, newborn; np, no product; TR, trauma; SIDS, sudden infant death syndrome. Upper panels show MSP results, lower panels calibration series for semiquantitative methylation specific PCR analysis. For semiquantitative MSP clones representing completely methylated and unmethylated DNA were mixed at ratios as indicated (%). While for RASSF1A tumors consistently show a higher degree of methylation than normal tissue CASP8 is methylated in normal brain and in tumor tissues. DNA from frozen tissues was isolated as published (Fru¨hwald et al., 2001b) ; from paraffin-embedded tissues DNA was isolated after treatment with xylene (Merck, Darmstadt, Germany), followed by centrifugation and digestion in proteinase K (Roche, Mannheim, Germany) and an isolation buffer (75 mM NaCl, 25 mM EDTA pH 8, 0.5% Tween 20). After phenol/chloroform extraction DNA was washed with 70% ethanol. DNA from cell lines was obtained by a QIAGEN DNA-isolation Kit (Qiagen, Hilden, Germany). Bisulfite treatment was as published (Fru¨hwald et al., 2001b) . Primers for RASSF1A and CASP8 were from (Teitz et al., 2000; Burbee et al., 2001) . Images of ethidiumbromide stained gels were obtained with a GelDoc System (Bio-Rad, Hercules, CA). Densitometry was performed using the Strip Densitometry Mode of tnimage by TJ Nelson (http:// brneurosci.org/tnimage.html).
Aberrant methylation of RASSF1A in sPNET and AT/RT J Mühlisch et al at all CpG sites evaluated by sequencing. This picture was not as clear for AT/RT. However, in comparison to normal brain samples all AT/RT exhibited a higher degree of methylation (86.6% of all CpGs in all sequenced clones were methylated), correlating with the near-complete methylation detected by MSP (Table 2b , Figure 3 ). These findings clearly withstood rigorous statistical evaluation, regardless of whether performed on the raw or the calibrated data. While methylation levels among normal tissues and among tumors differed insignificantly, there was a statistically relevant difference between methylation in tumors and normal brain. We calculated P-values below 0.001 for comparison of the methylation of RASSF1A in normal cerebellum on one side and AT/RT, sPNET and cell lines on the other (Mann-Whitney rank sum test). When comparing normal cortex to sPNET, cell lines and AT/RT the P-values were 0.002, 0.005 and 0.006, respectively. Semiquantitative RT-PCR demonstrated strong expression of RASSF1A in normal appearing brain samples from infants and children, while expression was weak in control tissues from older individuals (Figure 4a ). The cerebellar tissue of three individuals above 60 years showed rather low RASSF1A expression Figure 2 Results of a calibration MS-PCR approach for the genes RASSF1A and CASP8 in normal appearing brain and in embryonal brain tumors. Methylation levels were determined by comparison to a calibration curve created by mixing cloned PCR products of the methylated and unmethylated MSP reaction. PCR products were purified using a Gel Extraction Kit (Qiagen, Hilden). PCR products were cloned into a pCR2.1 vector (TA Cloning kit, Invitrogen Karlsruhe) and used to transform DH5a cells (Sambrook et al., 1989) . The identity of the clones (methylated vs unmethylated) was confirmed by sequencing. Relative methylation levels (M rel ) were obtained from densitometry readings of PCR bands and calculated according to M rel ¼ M/(U þ M). Next to each series mean and s.d. values are shown to illustrate the methylation distribution. While for RASSF1A a clear pattern of tumor vs normal tissue exists, the distribution appears heterogeneous for CASP8 (CE, cerebellum and CM, cerebral cortex). For statistics each continuous variable was analysed for its distribution ('Kolmogorov-Smirnov-test'). The Mann-Whitney Rank Sum test was used for comparison of pairs of variables (e.g. normal controls vs sPNET or AT/RT). Data were evaluated using SigmaStat Software Release (SPSS Inc., Chicago). Continuous variables are presented as the mean of three measurements. Differences were considered significant at a level of Po0.05. Aberrant methylation of RASSF1A in sPNET and AT/RT J Mühlisch et al (samples 6, 7 and 8; Figure 4a ). Weak to virtually absent expression was also seen in two sPNET (No 1 and 6, Figure 4a ), both of which had shown aberrant methylation by MSP. 5AZA treatment resulted in re-expression of RASSF1A in the medulloblastoma cell line D341Med and the renal rhabdoid cell line G401 (Table 2c ). The AT/RT-derived cell line BT16 did not re-express the gene following 5AZA alone. Using a combination of the DNMTase inhibitor 5AZA and the histone deacetylase inhibitor TSA led to re-expression of RASSF1A (Figure 4b ). We also studied a 5 0 CG-rich region of the CASP8 gene that has previously been described to correlate with gene expression even though it is not located in the promoter region of the gene and does not meet established criteria for CpG islands (Teitz et al., 2000; Banelli et al., 2002) . Just as Lindsey et al. in MB, we found methylation for CASP8 in normal appearing cerebella and cerebra (Table 1) (Lindsey et al., 2004) . Using a calibration series, we found that most normal tissues regardless of age showed some degree of methylation. The cerebella of four children showed even stronger methylation reaching 25-51% (Table 1 and Figure 2 ). The cortical tissue of two younger children (7 months and 2 years) revealed complete methylation of CASP8, while normal cortex of a 36 gestational weeks and a 5-year-old exhibited methylation above 50%. In all, 8/24 primary sPNET showed methylation corresponding to a level of more than 50%, while nine showed levels clearly below 5%, a level typically detected in normal brain samples. In all, 3/6 AT/RT displayed methylation levels above 50% and one of 99%. The rest was predominantly unmethylated (p5%). CASP8 thus appears to be methylated at a lower degree in AT/RT than sPNET, even though no statistical difference could be calculated. (Figure 2) .
Semiquantitative RT-PCR experiments demonstrated weak expression in all normal cerebella, while only one sPNET showed a weaker band (Figure 4a) .
Interestingly, and in contrast to the results obtained for RASSF1A the MSP results for CASP8 did not correlate with those of bisulfite sequencing (Figure 3 ). It showed a fluctuating pattern of methylated cytosine residues (in the priming sites and elsewhere), which might influence the efficiency of MSP and therefore be responsible for the less homogeneous methylation pattern observed. Accordingly statistical analysis could not detect any relevant differences between normal tissue and tumor tissues for this potential regulatory region of CASP8.
Our data have a number of important implications. For certain risk groups of the most common embryonal CNS tumor, medulloblastoma, cure rates of up to 70% have been achieved (Kortmann et al., 2000) . For other types such as the ones in our study sPNET and AT/RT prognosis remains grim and metastasis at diagnosis or relapse are inevitably fatal (Packer et al., 2002; Fru¨hwald et al., 2004) . While research has produced a series of potentially useful biomarkers for medulloblastoma, no such data is available for sPNET or AT/RT (Scheurlen et al., 1998; Grotzer et al., 2000) . Molecular data on sPNET are in fact extremely sparse in the literature and mostly restricted to case reports and cytogenetic studies (Bayani et al., 2000) . AT/RT have recently gained attention as a novel tumor suppressor gene candidate (SMARCB1) appears to be involved in the pathogenesis of these tumors, even though not all AT/RT seem to harbor mutations of that gene Figure 3 Bisulfite sequencing of promoter sequences of RASSF1A and a CG rich region of the CASP8 gene. In all, 10-30 ng of the PCR product were used with 1.5 pmol of forward primer using the Big Dye Terminator chemistry v3.1 (Applied Biosystems, Foster City, CA). Sequences were compared to completely methylated bisulfite treated DNA and verified in the raw data view to rule out artefacts and to detect incomplete bisulfite conversion. Closed circles, unchanged CpG residues indicative of methylation. X, not read by sequence analysis. Open circles, represent cytosine converted to thymine and thus absence of methylation. RASSF1A exhibits almost no methylation for normal brain (CE, cerebellum and CM, cerebral cortex), while the tumors are strongly methylated. In contrast the CpG rich region of CASP8 is methylated very heterogeneously and without correlation to the tissue type.
Aberrant methylation of RASSF1A in sPNET and AT/RT J Mühlisch et al (Fru¨hwald et al., 2005, Pediatric Blood and Cancer, in press ).
Our study is thus the first to evaluate in a gene candidate approach aberrant methylation of two specific genes (RASSF1A and CASP8) in sPNET and AT/RT. We chose these genes as they have previously been shown to be aberrantly methylated in the most common embryonal CNS tumor of childhood medulloblastoma ( 
2002
) and as both genes clearly exhibit characteristics of tumor suppressor genes (Teitz et al., 2000; Agathanggelou et al., 2005) . As is inherent to pilot studies like ours, we were not able to collect fresh frozen tissue from most samples, which would be optimal for molecular studies, but had to rely on paraffin embedded tissue resources mainly. As we used control samples from children of different age groups and different brain regions we should be able to avoid false positive methylation information caused by age-specific methylation patterns and to identify tissue-specific methylation.
As Lusher et al.'s and Harada et al.'s studies in MB, we detected aberrant methylation of the RASSF1A promoter in the majority of sPNET and AT/RT, but not in normal appearing brain samples (Harada et al., 2002a; Lusher et al., 2002) . Thus far no other gene has consistently been found aberrantly methylated in these entities. In the first and only other study specifically mentioning methylation analysis of sPNET, we were able to demonstrate partial methylation of p16
INK4a and CDH1 in a small series of five sPNET (Fru¨hwald et al., 2001b) . However, in the same study, we found that a significant number of promoter-associated CpG islands become hypermethylated in sPNET. Up to now RASSF1A is thus the first gene with demonstrated hypermethylation in these tumors.
In contrast to RASSF1A there was a discrepancy between MSP and bisulfite sequencing results for CASP8. Furthermore, methylation levels fluctuated among tumors and normal controls contradicting a tumor specific pattern, which was so clearly observed for RASSF1A. The lack of a correlation between MSP and bisulfite sequencing might be explained by varying degrees of methylation levels in the priming sites for the MSP primers (supplementary data not shown). The irregular degree of methylation in normal and tumor tissues may indicate that this region has no regulatory role in the sPNET and AT/RT. It could be argued that we did not assess the promoter region of the gene as has been discussed (Banelli et al., 2002) . However, we studied a CG-rich region that has been evaluated by others and found to be correlated with gene expression especially in embryonal tumors of childhood (Harada et al., 2002b; Zuzak et al., 2002) . For instance Harada Figure 4 (a) Expression analysis of CASP8 and RASSF1A in normal appearing brain and sPNET. cDNA was tested and normalized by amplification of GPI. Primers as published (Fru¨hwald et al., 2000; Teitz et al., 2000; Burbee et al., 2001) . cDNA (1 ml) was added to 0.4 mM of each primer, 0.4 mM dNTPs, 4% DMSO, 2 mM MgCl 2 and 1.25 U Platinum Taq in 25 ml of buffer (200 mM Tris-HCl pH 8.4 500 mM KCl, Invitrogen, Karlsruhe). PCR was: 951C, 10 min, (961C, 30 s, Ta 30s, 721C 1 min) Â 35, 721C, 5 min, 41C hold Ta (GPI) 621C, Ta (CASP8) 561C; RASSF1A: Touchdown-PCR, Ta (RASSF1A) (70-601C) 20 Â , for each cycle the annealing temperature was decreased by 0.51C, 601C 15 Â . For RASSF1A a tendency with lower expression in the control tissues from older individuals (6, 7 and 8) and in two of the tumor samples (1, 6) is observed. No clear pattern can be observed for CASP8. RNA was isolated by RNeasy Kit (Qiagen, Hilden, Germany). Total RNA (1.5 mg) was reverse transcribed using a mixture of random hexamers and oligo(dT) primers (Thermoscript RT-PCR-System, Invitrogen, Karlsruhe). After denaturation a master mix was added (Thermoscript 15 U, 4 ml 5 Â cDNA buffer, 1 ml of 0.1 M DTT, 40 U RNAseOUT and 2 ml 10 mM dNTPs). Random hexamers were annealed at 251C, 10 min and synthesis run at 501C, 50 min, while the oligo(dT)20 primers annealed and synthesized at 501C, 60 min. (b) Epigenetic silencing of RASSF1A in the rhabdoid cell line BT16. Treatment of the AT/ RT-derived cell line BT16 with the demethylating agent 5-Aza-2 0 -deoxycytidine (Aza) and the histone deacetylase inhibitor trichostatin (TSA) resulted in re-expression of RASSF1A. D341Med, MHH-PNET5, PFSK, G401, 7.92, BT12 and BT16 were cultured with either 5AZA alone or in combination with TSA. 5AZA concentrations ranged from 1 to 40 mM, TSA from 0.1 to 0.8 mM. RNA was isolated after 24 and 72 h. D341Med (medulloblastoma), 7.92 (renal rhabdoid tumor), PFSK (sPNET) ATCC, Rockland MD. MHH-PNET5 by T Pietsch (University of Bonn, Germany). G401 (renal rhabdoid) by K Brown (University of Bristol, UK), BT12, BT16 (both AT/RT) by D Reardon and J Biegel (St Jude Children's Hospital, Tennessee and Children's Hospital of Philadelphia, Pennsylvania). demonstrated a correlation between a lack of mRNA expression and methylation. As we demonstrated aberrant methylation of this region in normal brain as well as in sPNET and AT/RT the relevance of the gene or this potential regulatory region in tumorigenesis of these specific entities has at least to be questioned. We suggest that the study of aberrant methylation in large series of normal appearing control tissues should be used to normalize data on this phenomenon in other CNS tumors of childhood such as ependymoma and MB. We cannot exclude that other epigenetic lesions such as the action of histone deacetylases or the regulation by epigenetically controlled transcription factors are responsible for the silencing of CASP8 in medulloblastomas as has been described by Zuzak et al. (2002) . This may explain why treatment with interferon can reactivate the expression of CASP8 in cell lines (Pingoud-Meier et al., 2003) . It remains to be determined if this phenomenon is a tissue-specific vs a neoplasm-specific event.
In contrast to other studies, we attempted a semiquantitative analysis using a calibration series. The calibration series allowed us to differentiate methylation signals emanating from low abundant methylated DNA, overestimated by MSP, from methylation signals representing methylation of more than 5%. Comparison of bisulfite sequencing with calibrated MSP revealed an excellent concordance. For methylation levels at the border of detectability more quantitaive methodologies are certainly desirable.
Unfortunately, we could not test expression in a larger cohort due to the lack of fresh frozen tissue. While the expression data in primary tumors are thus clearly preliminary the results of re-expression analyses in combination with those on primary tumors are suggestive of epigenetic regulation for RASSF1A, but not CASP8 in sPNET and AT/RT. Through the advent of epigenetically active therapeutic substances such as demethylating agents and histone modifying drugs it may become possible to reverse these changes (Egger et al., 2004) . As the prognosis for sPNET and AT/RT remains dismal epigenetic treatment bears great potential. The proposed agents are target oriented towards developmentally regulated processes and oral preparations are in phase I or II clinical trials (Kelly et al., 2005; Melnick et al., 2005) .
These data represent some of the first hints towards molecular defects in defined genes in sPNET. As aberrant methylation plays an important role during normal development it is likely that aberrant regulation may cause the formation of irregularly proliferating cell clones (Fru¨hwald and Plass, 2002) . Likewise our data give a first hint that genes other than SMARCB1 (INI1/ SNF5) may be involved in the pathogenesis of AT/RT. Successful re-expression of the gene in a cell line derived from a renal rhabdoid tumor and one from an AT/RT suggests further studies into this phenomenon. The gene SMARCB1 plays an important role in histone remodeling influencing gene expression (Sevenet et al., 1999) . A link to DNA methylation has yet to be established.
Taken together, we present first evidence that aberrant methylation of RASSF1A may play a role in the origin of the embryonal CNS tumors sPNET and AT/RT. Further studies may have important bearings in elucidating the origin of these neoplasms and may also lead to novel therapeutic approaches. Continued examination of epigenetic inactivation mechanisms in these tumors is beyond any doubt worthwhile.
